Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Mahlangu, Johnny; Oldenburg, Johannes; Paz‐Priel, Ido; Négrier, Claude; Niggli, Markus; Elisa Mancuso, Maria; Schmitt, Christophe; Jiménez‐Yuste, Víctor; L. Kempton, Christine; Dhalluin, Christophe; U. Callaghan, Michael; Buján, Willem; Shima, Midori; I. Adamkewicz, Joanne; Asikanius, Elina; G. Levy, Gallia; Kruse‐Jarres, Rebecca

doi:10.1056/nejmoa1803550

Public

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Published in New England Journal of Medicine • Aug 29, 2018

Authors:

Johnny Mahlangu

Johannes Oldenburg

Ido Paz‐Priel

Abstract

BACKGROUND: Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis in persons who have hemophilia A wi...

Subject

Medicine

Confidence interval

Group B

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!